Cargando…

Fabry disease and COVID-19: international expert recommendations for management based on real-world experience

Mostrar otras versiones (1)

The rapid spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has raised questions about Fabry disease (FD) as an independent risk factor for severe COVID-19 symptoms. Available real-world data on 22 patients from an international group of healthca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laney, Dawn A, Germain, Dominique P, Oliveira, João Paulo, Burlina, Alessandro P, Cabrera, Gustavo Horacio, Hong, Geu-Ru, Hopkin, Robert J, Niu, Dau-Ming, Thomas, Mark, Trimarchi, Hernán, Wilcox, William R, Politei, Juan Manuel, Ortiz, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Special Feature
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769541/ https://www.ncbi.nlm.nih.gov/pubmed/33391734 http://dx.doi.org/10.1093/ckj/sfaa227

Ejemplares similares

Fabry disease and COVID-19: International expert recommendations for management based on real-world experience
por: Laney, Dawn A., et al.
Publicado: (2021)

Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
por: Politei, Juan M., et al.
Publicado: (2016)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
por: Bichet, Daniel G., et al.
Publicado: (2023)

Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel
por: Burlina, Alessandro P, et al.
Publicado: (2011)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup
por: Germain, Dominique P, et al.
Publicado: (2020)

Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
por: Germain, Dominique P., et al.
Publicado: (2018)

Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies
por: Thurberg, Beth L., et al.
Publicado: (2016)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience
por: Gragnaniello, Vincenza, et al.
Publicado: (2021)

Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes
por: Trimarchi, Hernán, et al.
Publicado: (2018)

Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients
por: Germain, Dominique P., et al.
Publicado: (2019)

The benefits and challenges of family genetic testing in rare genetic diseases—lessons from Fabry disease
por: Germain, Dominique P., et al.
Publicado: (2021)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued
por: Politei, Juan
Publicado: (2020)

The Limitations of the Expert
por: Laski, Harold J.
Publicado: (2020)

Increased urinary CD80 excretion and podocyturia in Fabry disease
por: Trimarchi, H., et al.
Publicado: (2016)

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations
por: Greco, Raffaella, et al.
Publicado: (2021)

Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
por: Gal, Andreas, et al.
Publicado: (2011)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Newborn Screening for Fabry Disease: Current Status of Knowledge
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Attention Deficits and ADHD Symptoms in Adults with Fabry Disease—A Pilot Investigation
por: Ali, Nadia, et al.
Publicado: (2021)

Fibrosis: a key feature of Fabry disease with potential therapeutic implications
por: Weidemann, Frank, et al.
Publicado: (2013)

The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status
por: Martins, Ana M., et al.
Publicado: (2019)

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group
por: Mohty, Mohamad, et al.
Publicado: (2019)

International Consensus Recommendation Guidelines for Subcutaneous Infusions of Hydration and Medication in Adults: An e-Delphi Consensus Study
por: Broadhurst, Daphne, et al.
Publicado: (2023)

Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease
por: Hamed, Alaa, et al.
Publicado: (2021)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Development of the Fabry Disease Patient-Reported Outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease
por: Hamed, Alaa, et al.
Publicado: (2021)

Patient Education Regarding Fasting Recommendations to Shorten Fasting Times in Patients Undergoing Esophagogastroduodenoscopy: A Controlled Pilot Study
por: van Noort, Harm H. J., et al.
Publicado: (2022)

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
por: Sharrack, Basil, et al.
Publicado: (2019)

A Text-Mining Analysis to Examine Dominant Sources of Online Information and Content on Continuous Glucose Monitors
por: Heitkemper, Elizabeth M., et al.
Publicado: (2023)

Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts
por: Germain, Dominique P., et al.
Publicado: (2019)

Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion
por: August, Gilbert P., et al.
Publicado: (2008)

FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease
por: Mignani, Renzo, et al.
Publicado: (2016)

Aortic arch stiffness in Fabry disease
por: Bensalah, Zoubir M, et al.
Publicado: (2013)

The Age-Well observational study on expert meditators in the Medit-Ageing European project
por: Lutz, Antoine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b8mk8pjcks7qcfc73jui2m2hop